MedinCell: an analyst persists and signs




By




The 2023-2024 half-year accounts of MedinCell showed revenues of 8.2 ME (+6.1% compared to the first half of the previous year), including 7 ME in turnover. These revenues come from the payment of a milestone of 3.6 ME for marketing authorization by the American FDA…

This stock market news is reserved for subscribers Privileges


Test our stock market advice for €1, without obligation


I subscribe

Already subscribed? Log in

Discover Boursier.com services Privileges


  • 8:30 a.m.
    Today’s recce

  • 4 to 5 stock market tips per day


    4 to 5 tips
    scholarship holders per day

  • weekly letter “Opportunities”


    Weekly letter “Opportunities”



  • Wallets
    defensive, balanced
    and dynamic


Learn more


©2023 Boursier.com



Source link -87